Eur Rev Med Pharmacol Sci 2016; 20 (6): 1064-1070

Advance in the study on p38 MAPK mediated drug resistance in leukemia

F. Gao, W.-J. Liu

Department of Pediatrics of Affiliated Hospital of Sichuan Medical University, Luzhou, Sichuan Province, China. liuwenjunsc@163.com

Leukemia is a group of malignant clone diseases of hematopoietic stem cells, while drug resistance (DR) has become the primary cause of chemotherapy failure. p38 mitogen-activated protein kinase (p38MAPK) signaling pathway induces cell activation, proliferation and apoptosis in response to extracellular stimuli. Recent studies have shown that p38 MAPK signaling pathway is closely associated with DR in leukemia. The present article reviews the relationship between p38 MAPK signaling pathway and DR in leukemia.

Free PDF Download

To cite this article

F. Gao, W.-J. Liu
Advance in the study on p38 MAPK mediated drug resistance in leukemia

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 6
Pages: 1064-1070

Keywords Related articles:

  1. Mechanism of resistance and therapeutic prospect of leukemia mediated by signaling pathway in bone marrow microenvironment
  2. miR-181a down-regulates MAP2K1 to enhance adriamycin sensitivity in leukemia HL-60 cells
  3. MiR-143 regulates proliferation and apoptosis of myelocytic leukemia cell HL-60 via modulating ERK1
  4. Targeted regulation of miR-195 on MAP2K1 for suppressing ADM drug resistance in prostate cancer cells
  5. Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology